- Biotechnology company Destiny Pharma said it had joined forces with MedPharm to develop new topical formulations from the company's antimicrobial XF-platform.

The move comes as the company had identified an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced level of antimicrobial resistance.

MedPharm would develop new formulations containing Destiny Pharma's XF-platform compounds for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

'We look forward to developing improved, targeted formulations with MedPharm to take into future pre-clinical and clinical studies,' the company said.

The XF platform had already delivered a Phase 2 ready candidate, XF-73 nasal gel, for the prevention of post-surgical infections, that would begin Phase 2b testing in 2019, Destiny Pharma said.

At 8:49am: [LON:DEST] Destiny Pharma Plc share price was +0.5p at 83p

Story provided by